Press Releases

Attenua Raises $35M in Series A Financing to Advance Therapy for Chronic Cough

• $35M Series A financing led by Omega Funds, with participation from Abingworth, OrbiMed and Redmile Group • Michael Kitt, MD, former Chief Medical Officer at Afferent Pharmaceuticals, joins as CEO Mountain View, California, Apr. 30, 2018 – Attenua, Inc., a clinical-stage biopharmaceutical company focused on developing novel medicines to treat cough, today announced the completion [...]

April 30th, 2018|

Attenua Announces Release of Data Demonstrating that ATA-101 is Antitussive in Guinea Pigs

NEW YORK, Sept. 11, 2017 /PRNewswire/ -- Attenua, a clinical-stage biopharmaceutical company focused on developing novel, non-narcotic medicines for cough – a significant and unmet medical problem, today announced the release of novel data that demonstrate the antitussive effectiveness of its lead compound – ATA-101. Results will be presented at the European Respiratory Society International Congress [...]

September 12th, 2017|

Catalyst Biosciences Announces Agreement to Sell Three NNR Assets to Attenua

-- Divestment of Certain Neuronal Nicotinic Receptor Assets to Provide Catalyst with $1 Million Up Front Payment -- -- Catalyst Remains Focused on Core Therapeutic Areas, Especially Hemophilia -- SOUTH SAN FRANCISCO, Calif., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on creating and developing novel medicines to address [...]

September 13th, 2016|